Carmot Therapeutics
Carmot Therapeutics is a biopharmaceutical company developing disease-modifying therapies for metabolic diseases, particularly obesity and type 2 diabetes. Its Chemotype Evolution discovery platform produced a portfolio of incretin receptor modulators, led by CT-388, a once-weekly injectable dual GLP-1/GIP receptor agonist, alongside CT-868, a once-daily injectable dual GLP-1/GIP receptor agonist, and CT-996, a once-daily oral small-molecule GLP-1 receptor agonist. Carmot has been a wholly owned subsidiary of Roche since Roche completed its $2.7 billion acquisition of the company in January 2024.
Acquired
Carmot Therapeutics has been acquired
This company is no longer available on our private secondary market.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2008
Employees
51–200
Total Funding
$372.1M
6 rounds
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $372.1M across 6 rounds
Last updated 10-01-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| May 25, 2023 | Series E | $150M | — | Deep Track Capital |
| Jul 26, 2022 | Series D Press release | $130.4M | — | The Column Group, RA Capital Management |
| Oct 2021 | Convertible Notes | $30M | — | Not disclosed |
Prominent Investors
Leadership
Heather Turner
President and Chief Executive Officer
Michael Gray
Chief Operating Officer and Chief Financial Officer
Manu Chakravarthy
Chief Medical and Scientific Officer
Stig K. Hansen
Co-founder and Director; former Chief Executive Officer
Daniel Erlanson
Co-founder
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.